WHO ICTRP trial
Clinical and Health Assessments with BLISibimod SC, Study 1
KCT0000967 · Clinical Research Information Service (CRIS) · Recruiting
Key facts
| Trial ID | KCT0000967 |
|---|---|
| Public title | Clinical and Health Assessments with BLISibimod SC, Study 1 |
| Scientific title | A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects with Systemic Lupus Erythematosus |
| Primary sponsor | Anthera Pharmaceuticals |
| Registry | Clinical Research Information Service (CRIS) |
| Recruitment status | Recruiting |
| Study type | Interventional Study |
| Phase | Phase3 |
| Countries | Korea, Republic of |
| Conditions | Diseases of the blood and blood -forming organs and certain disorders involving the immune mechanism |
| Interventions | Biological/Vaccine, Non-Stem Cell : Blisibimod 200mg or placebo will be administered subcutaneously (SC) weekly for 52 weeks |
| Registration date | Dec 20, 2013 |
| Target size | 30 |
| Secondary IDs | NCT01395745 |
| Registry page | cris.nih.go.kr |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: